SCHEMBL21098668

SCHEMBL21098668

COc1cc(OCCCC(=O)O)cc2c1C(=O)CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.40
FFAR1 O14842 2/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
MAOB P27338 4/20 0.39
MAOA P21397 2/20 0.39
MCL1 Q07820 1/20 0.38
TSHR P16473 3/20 0.38
MAPT P10636 1/20 0.38
FFAR4 Q5NUL3 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21098943 0.86 BRD4 (0.52) KDM4ETSHRNPC1LMNAGAA
SCHEMBL21098681 0.84 RXRA (0.41) KDM4EPOLBMAOBMAOAMCL1
SCHEMBL21099222 0.82 FFAR4 (0.40) FFAR1KDM4EPOLBMAOBMAOA
SCHEMBL228911 0.78 MEN1 (0.53) MAOAMAPTMEN1KMT2AGAA
SCHEMBL22815495 0.76 MEN1 (0.41) KDM4EMAOBMAOATSHRMAPT
SCHEMBL21052437 0.76 ALB (0.42) PPARDFFAR1PPARGPPARAMAOB
SCHEMBL21052066 0.74 MAOB (0.67) MAOBMAOAFFAR4
SCHEMBL21098676 0.74 FFAR4 (0.41) FFAR1MAOBMCL1FFAR4
SCHEMBL5843043 0.74 POLB (0.54) PPARDFFAR1PPARGPPARAPOLB
SCHEMBL22773712 0.73 MAOA (0.41) KDM4EPOLBMAOBMAOATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11576981-B2 Acyl hydrazone linkers, methods and uses thereof ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2023-02-14 US disclosed
US-20200397916-A1 ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2020-12-24 US disclosed
WO-2019109188-A1 ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2019-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200397916-A1 ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF KAT7, AADAC, HDAC7 PPARD 2646/4885FFAR1 3835/4885PPARG 1751/4885
US-11576981-B2 Acyl hydrazone linkers, methods and uses thereof AADAC, HDAC8, KAT8 PPARD 2904/4885FFAR1 3745/4885PPARG 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.